Inhibition of enzymes in the pharmacological treatment in of benign prostatic hyperplasia;Inhibice enzymů ve farmakoterapii benigní hyperplazie prostaty

Casopis Lekaru Ceskych

Volumn 141, Issue 20, 2002, Pages 630-635

  Dršata, Jaroslav ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

5 reductase; Aromatase; Benign prostatic hyperplasia; Enzyme inhibitors; Pharmacotherapy; Phytopharmaceuticals

Indexed keywords

ANDROGEN; ANDROSTANOLONE; AROMATASE; CHOLEST 4 EN 3 ONE; ESTROGEN; FINASTERIDE; ISOENZYME; POLYUNSATURATED FATTY ACID; PROGESTERONE; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; STEROID; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; URTICA EXTRACT;

DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HORMONE METABOLISM; PROSTATE HYPERTROPHY; REVIEW;

CHOLESTENONE 5 ALPHA-REDUCTASE; ENZYME INHIBITORS; HUMANS; MALE; OXIDOREDUCTASES; PROSTATIC HYPERPLASIA;

EID: 0036437690     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Dvořáček, J.: Současné farmakoterapeutické možnosti léčby benigní hyperplazie prostaty. Remedia, 9, 1999, s. 7-12.
2. Veselský, Z.: Možnosti farmakologického ovlivnění benigní hyperplazie prostaty. Medicína, 7, 2000, s. 17.
3. Anonymous: Léčba benigní hyperplazie prostaty. Farmakoterapeutické Informace, 3, 1996, s. 1-4.
4. Kawaciuk, I.: O medikamentózní léčbě benigní hyperplazie prostaty. Lege Artis, 2000, s. 26-29.
5. Michal, G. (ed.): Biochemical Pathways. An Atlas of Biochemistry and Molecular Biology, Wiley, New York 1999, s. 93-94.
6. http://www.chem.qmw.ac.uk/iubmb/enzyme/
7. Shefer, S., Hauser, S., Mosbach, E. H.: Studies on the biosynthesis of 5-alpha-cholestan-3-beta-ol. I. Cholestenone 5-alpha-reductase of rat liver. J. Biol. Chem., 241, 1966, s. 946-952.
8. Enderle-Schmitt, U., Neuhaus, C., Aumüller, G.: Solubilization of nuclear steroid 5 alpha-reductase from rat ventral prostate. Biochim. Biophys. Acta, 987, 1989, s. 21-28.
9. Moore, R. J., Wilson, J. D.: Reduced nicotinamide adenine dinucleotide phosphate: delta4-3-ketosteroid 5alpha-oxidoreductase (rat ventral prostate). Methods Enzymol., 36A, 1975, s. 466-474.
10. Watkins, W. J., Goldring, C. E. P., Gower, D. B.: Properties of 4-ene 5-α-reductase in porcine testicular microsomes. Biochem. Soc. Trans., 14, 1986, s. 339-340.
11. Watkins, W.J., Gower, D. B.: Δ4-Steroid 5-α-reductase activity in porcine testicular microsomes. Biochem. Soc. Trans., 13, 1985, s. 187-188.
12. Frederiksen, D. W., Wilson, J. D.: Partial characterization of the nuclear reduced nicotinamide adenine dinucleotide phosphate: Delta 4-3-ketosteroid 5 alpha-oxidoreductase of rat prostate. J. Biol. Chem., 246, 1971, s. 2484-2593.
13. Watkins, W. J., Wilson, L., Gower, D. B.: Solubilization of 4-ene 5-α-reductse from porcine testicular microsomes. Biochem. Soc. Trans., 14, 1986, s. 979.
14. Wilton, D. C.: Is a Schiff base involved in the mechanism of the delta4-3-oxo steroid 5alpha- or 5beta-reductases from mammalian liver? Biochem. J., 155, 1976, s. 487-491.
15. Graef, V., Golf, S. W., Tüschen, M.: NADPH: 4-ene-3-oxosteroid-5 alpha-reductase and NADH: 4-ene-3-oxosteroid-5 alpha-reductase in liver microsomes of different species of animals. J. Steroid Biochem., 14, 1981, s. 883-887.
16. Lotz, W.: Importance of 5 alpha-reduction for the trophic effects of androgens on rat accessory sex organs and LH control. J. Steroid Biochem., 13, 1980, s. 1261-1264.
17. Sholiton, L. J., Grossman, C. J., Taylor, B. B.: Rat thymic homogenates convert testosterone to androgenic metabolites. J. Steroid Biochem., 13, 1980, s. 1365-1367.
18. Thoubenot,D., Morfin, R. F.: Interferences of zearalenone, zearalanol or estradiol-17 beta with steroid-metabolizing enzymes of the human prostate gland. J. Steroid Biochem., 13, 1980, s. 1337-1345.
19. Kondo, K., Aono, T., Furubayashi, Y. et al.: Hormonal regulation of activities of 4-ene-5 alpha-reductase and 17 beta-o1-dehydrogenase in adult androgen-sterilized rat ovaries. J. Steroid Biochem., 13, 1980, s. 703-705.
20. Blohm, T. R., Metcalf, B. W., Lauglin, M. E. et al.: Inhibition of testosterone 5 alpha-reductase by a proposed enzyme-activated, active site-directed inhibitor. Biochem. Biophys. Res. Commun., 95, 1980, s. 273-280.
21. Koninckx, P., Verhoeven, G., Heyns, W., De Moore, P.: Biochemical characterization of the NADPH: 4-ene-3-ketosteroid 5 alpha-oxidoreductase in rat ovarian suspension cultures. J. Steroid Biochem., 10, 1979, s. 325-333.
22. Voigt, W., Hsia, S. I.: Further studies on testosterone 5-reductase of human skin. Structures features of steroid inhibitors. J. Biol. Chem., 248, 1973, s. 4280-4285.
23. Moore, R. J., Wilson, J. D.: Steroid 5alpha-reductase in cultured human fibroblasts. Biochemical and genetic evidence for two distinct enzyme activities. J. Biol. Chem., 251, 1976., s. 5895-5900.
24. Wallace, A. M., Grant, J. K.: Effect of zinc on androgen metabolism in human hyperplastic prostate. Biochem. Soc. Trans., 3, 1975, s. 540-542.
25. Moore, R. J., Wilson, J. D.: Extraction of the reduced nicotinamide adenine dinucleotide phosphate: Delta 4-3-ketosteroid-5-alpha oxidoreductase of rat prostate with digitonin and potassium chloride. Biochemistry, 13, 1974, s. 450-456.
26. Scheer, H., Robaire, B.: Solubilization and partial characterization of rat epididynal delta 4-steroid 5 alpha-reductase (cholestenone 5 alphareductase). Biochem. J., 211, 1983, s. 65-74.
27. Cowan, R. A., Cook, B., Cowan, S. K. et al.: Testosterone 5 alphareductase and the accumulation of dihydrotestosterone in benign prostatic hyperplasia. J. Steroid Biochem., 11, 1979, s. 609-613.
28. Jurman, M. E., Erulkar, S. D., Krieger, N. R.: Testosterone 5 alpha-reductase in spinal cord of Xenopus laevis. J. Neurochem., 38, 1982, s. 657-661.
29. Andersson, S., Russell, D. W.: Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc. Nat. Acad. Sci. U.S.A., 87, 1990, s. 3640-3644.
30. Labrie, F., Sugimoto, Y., Luu-The, V. et al.: Structure of human type II 5α-reductase gene. Endocrinology, 131, 1992, s. 1571-1573.
31. Normington, K., Russell, D. W.: Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. J. Biol. Chem., 267, 1992, s. 19548 až 19554.
32. Iehlé, C., Délos, S., Guirou, O. et al.: Human prostatic steroid 5α-reductase isoforms: A comparative study of selective inhibitors. J. Steroid Biochem. Mol. Biol., 54, 1995, s. 273-279.
33. http://www.brenda.umi-koeln.de/
34. Bertics, P. J., Karavolas, H. J.: Partial characterization of the microsomal and solubilized hypothalalamic progesterone 5 alpha-reductase. J. Steroid Biochem., 21, 1984, s. 305-314.
35. Bertics, P. J., Edman, C. F., Karavolas, H. J.: Potent inhibition of the hypotlahamic progesterone 5 alpha-reductase by a 5 alpha-dihydroprogesterone analog. J. Biol. Chem., 259, 1984, s. 107-111.
36. Campbell, J. S., Karavolas, H. J.: The kinetic mechanism of the hypothalamic progesterone 5 alpha-reductase. J. Steroid Biochem., 32, 1989, s. 283-289.
37. Cheng, Y.-J., Karavolas, H. J.: Subcellular distribution and properties of progesterone (delta4-steroid) 5alpha-reductase in rat medial basal hypothalamus. Biol. Chem., 250, 1975, s. 7997-8003.
38. Krause, J. E., Karavolas, H. J.: Subcellular location of hypothalamic progesterone metabolizing enzymes and evidence for distinct NADH and NAHDPH-linked 3 alpha-hydroxysteroid oxidoreductase activities. J. Steroid Biochem., 13, 1980, s. 271-280.
39. Bertics, P. J., Karavolas, H. J.: Pituitary progesterone 5 alpha-reductase: Solubilization and partial characterization. J. Steroid Biochem., 22, 1985, s. 795-802.
40. Cheng, Y.-J., Karavolas, H. J.: Properties and subcellular distribution of delta4-steroid (progesterone) 5alpha-reductase in rat anterior pituitary. Steroids, 26, 1975, s. 57-71.
41. Roselli, C. E., Snipes, C. A.: Progesterone 5 alpha-reductase in mouse brain. Brain Res., 305, 1984, s. 197-202.
42. Ichihara, K., Tanaka, C.: Specific stimulation of steroid 5 alpha-reductase solubilized from rat liver microsomes by endogenous phosphatidylserine. Biochem. Biophys. Res. Commun., 149, 1987, s. 482-487.
43. Holt, D. A., Levy, M. A., Ladd, D. L. et al.: Steroidal A ring aryl carboxylic acids: A new class of steroid 5 alpha-reductase inhibitors. J. Med. Chem., 33, 1990, s. 937-942.
44. Holt, D. A., Levy, M. A., Oh, H. J. et al.: Inhibition of steroid 5 alpha-reductase by unsaturated 3-carboxysteroids. J. Med. Chem., 33, 1990, s. 943-950.
45. Wendroth, S., Seitz, H. U.: Characterization and localization of progesterone 5 alpha-reductase from cell cultures of foxglove (Digitalis lanata EHRH). Biochem. J., 266, 1990, s. 41-46.
46. Levy, M. A., Brandt, M., Heys, J. R. et al.: Inhibition of rat liver steroid 5 alpha-reductase by 3-androstene-3-carboxylic acids: Mechanism of enzyme-inhibitor interaction. Biochemistry, 29, 1990, s. 2815-2824.
47. Randall, V. A.: Role of 5 alpha-reductase in health and disease. Baillieres. Clin. Endocrinol. Metab., 8, 1994, s. 405-431.
48. Imperato McGinley, J., Guerrero, L., Gautier, T., Peterson, R. E.: Steroid 5alpha-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science, 186, 1974, s. 1213-1215.
49. Metcalf, B. W., Holt, D. A., Levy, M. A. et al.: Potent inhibition of human steroid 5-α-reductase (EC 1.3.1.30) by androstene-3-carboxylic acids. Bioorg. Chem., 17, 1989, s. 372-376.
50. Dršata, J.: Katalyzovaná inhibice enzymů a mechanizmus účinku farmak. Čes. Slov. Farm., 43, 1994, s. 310-314.
51. Zerhouni, N. A., Maes, M., Sultan, C. et al.: Selective inhibition by secosteroids of 5 alpha-reductase activity in human sex skin fibroblasts. Steroids. 33, 1979, s. 277-285.
52. Petrow, V., Padilla, G. M., Mukherji, S., Marths, S. A.: Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone. J. Pharm. Pharmacol., 36, 1984, s. 352-353.
53. Roberson, K. M., Padilla, G. M., Schmidt, J. M. et al.: 6-Methylen progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity. Prostate, 26, 1995, s. 28-34.
54. Levy, M. A., Brandt, M., Sheedy, K. M. et al.: Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. J. Steroid Biochem. Mol. Biol., 48, 1994, s. 197-206.
55. Tuttle, R. M., Loop, S., Jones, R. E. et al.: Effect of 5-alúha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3. Prostate, 24, 1994, s. 229-236.
56. Bratoeff, E., Ramírez, E., Murillo, E. et al.: Steroidal antiandrogens and 5alúha-reductase inhibitors. Curr. Med. Chem., 6, 1999, s. 1107až 1123.
57. Brandt, M., Greway, A. T., Holt, D. A. et al.: Studies on the mechanism of steroid 5 alpha-reductase inhibition by 3-caroxy A-ring aryl steroids. J. Steroid Biochem. Mol. Biol., 37, 1990, s. 575-579.
58. Guarna, A., Belle, C., Machetti, F. et al.: 19-nor-10- azasteroids: A novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. J. Med. Chem., 40, 1997, s. 1112-1129.
59. Berges, R. R., Windeler, J., Trampisch, H. J., Senge, T.: Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet, 345, 1995, s. 1529-1532.
60. Jarman, M., Barrie, S. E., Houghton, J. et al.: Evaluation of some 4-fluoro- and 4-cyano derivatives of delta 4,3-ketosteroids as inhibitors of testosterone 5 alpha-reductase. J. Enzyme Inhib., 8, 1994, s. 17-23.
61. Brooks, J. R., Baptista, E. M., Berman, C. et al.: Response of rat ventral prostate to a new and novel 5α-reductase inhibitor. Endocrinology, 109, 1981, s. 830-836.
62. Ngyuen, M. M., Lemmi, C. A., Rajfer, J.: Effect of 5-aůúha-reductase inhibitor, 4-MAPC, on testicular descent in male rat. J. Urol., 145, 1991, s. 1096-1098.
63. Liang, T., Cascieri, M. A., Cheung, A. H. et al.: Species differences in prostatic 5α-reductase of rat, dog and human. Endocrinology, 117, 1985, s. 571-579.
64. Tian, G., Stuart, J. D., Moss, M. L. et al. 17 beta-(N-tert-butylcarbamoyl)-4-aza-5-alúha-androstan-1-en-3-one is an active sitedirected slow time-dependent inhibitor of human steroid 5 alpha-reductase 1. Biochemistry, 33, 1994, s. 2291-2296.
65. Délos, S., Iehlé, C., Martin, P. M., Raynaud, J. P.: Inhibition of the activity of "basic" 5α-reductase (type 1) detected in DU 145 cells and expressed in inset cells. J. Steroid Biochem. Molec. Biol., 48, 1994, s. 347-352.
66. Di Salle, E., Giudici, D., Briatico, G. et al.: Hormonal effects of turosteride, a 5α-reductase inhibitor, in the rat. J. Steroid Biochem. Molec. Biol., 46, 1993, s. 549-555.
67. Kattner, L., Göhring, S., Hartmann, R. W.: Synthesis and biochemical evaluation of (carbamoylalenyl)phenyloxy carbocylic acid derivatives as non-steroidal 5 alpha-reductase inhibitors. Arch. Pharm. (Weinheim), 328, 1995, s. 239-245.
68. Kojo, H., Nakayama, O., Hirosumi, J. et al.: Novel steroid 5 alphareductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes. Mol. Pharmacol., 48, 1995, s. 401-406.
69. Taylor, M. E., Bhattacharyya, A. K., Collins, D. C.: Inhibition of rat steroid 5 alpha-reductase (isozyme 1) by suramin. Steroids, 60, 1995, s. 452-456.
70. Hartmann, R. W., Reichert, M.: New nonsteroidal steroid 5 alpha-reductase inhibitors. Syntheses and structure-activity studies on carboxamide phenylalkyl-substituted pyridones and piperidones. Arch. Pharm. (Weiheim), 333, 2000, s. 145-153.
71. McNulty, A. M., Audia, J. E., Bemis, K. G. et al.: Kinetic analysis of LY320236: Competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5alpha-reductase. J. Steroid Biochem. Mol. Biol., 72, 2000, s. 13-21.
72. Liang, T., Liao, S.: Inhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acids. Biochem. J., 285, 1992, s. 557-562.
73. Fitzpatrick, J. M., Dreikorn, K., Khoury, S. et al.: The medical management of BPH with agents other than hormones or alfa-blockers. In Cockett et al.: The 2nd International Consultation on Benign Prostatic Hyperplasia, Paris 1993.
74. Sultan, C., Terraza, A., Devillier, C. et al.: Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J. Steroid Biochem., 20, 1984, s. 515 až 519.
75. Raynaud, J. P., Cousse, H., Martin, P. M.: Selectivity of free fatty acids on 5-α-reductase inhibitory activity (abstracts). J. Urology, 139, 1988 (Suppl. 5), s. 110.
76. 4) from human polymorphonuclear neutrophils. Prostaglandins Leukotrienes Essential Fatty Acids, 57, 1997, s. 299-304.
77. Lesuisse, D., Berjonneau, J., Ciot, C. et al.: Determination of eonothein B as the active 5-alpha-reductase-inhibiting principle of the folk medicine Epilobium parviflorum. J. Nat. Prod., 59, 1996, s. 490-492.
78. Liao, S., Hiipakka, R. A.: Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun., 214, 1995, s. 833-838.
79. Osawa, Y., Higashiyama, T., Fronckowiak, M. et al.: Aromatase. J. Steroid Biochem., 27, 1987, s. 781-789.
80. Brodie, A., Lu, Q., Long, B.: Aromatase and its inhibitors. J. Steroid Biochem. Mol. Biol., 69, 1999, s. 205-210.
81. Suchopár, J. (Ed.): Compendium Remedia, 2. Vydání, Panax, Praha 1999, s. 450.
82. Karr, J. P., Kaburagi, Y., Mann, C. F., Sandberg, A. A.: The potential significance of aromatase in the etiology and treatment of prostatic disease. Steroids, 50, 1987, s. 449-457.
83. Harada, N.: A new aspect of the pharmacological and physiological significance of the aromatase/estrogen system. Nippon Yakurigaku Zasshi. 112, 1998, s. 51-58.
84. Tsugaya, M., Harada, N., Tozawa, K. et al.: Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer. Int. J. Urol., 3, 1996, s. 292-296.
85. Schweikert, H. U., Tunn, U. W., Habenicht, U. F. et al.: Effects of estrogen deprivation on human benign prostatig hyperplasia. J. Steroid Biochem. Mol. Biol., 44, 1993, s. 573-576.
86. Radlmaier, A., Eickenberg, H. U., Fletcher, M. S. et al.: Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: Result of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate, 19, 1996, s. 199-208.
87. Suchopár, J. (Ed.): Compendium Remedia, 2. Vydání, Panax, Praha 1999, s. 430.
88. Sciarra, F., Toscano, V.: Role of estrogens in human benign prostatic hyperplasia. Arch. Androl., 44, 2000, s. 213-220.
89. Pirani, J. F.: The effects of phytotherapeutic agents on prostate cancer: An overview of recent clinical trials of PC spec. Urology, 58, 2001 (Suppl. 1), s. 36-38.
90. Cuellar, D. C., Kyprianou, N.: Future concepts in the medical therapy of benign prostatic hyperplasia. Curr. Opin. Urol., 11, 2001, s. 27-33.